example alt text

AIM Rules Compliance (Rule 26)

In accordance with AIM Rule 26, as stipulated by the London Stock Exchange, all AIM-quoted companies are required to disclose certain information on their corporate website.

In compliance with this rule, IS Pharma plc (incorporated in England & Wales registered number 3337415) has provided the following information on this site.

Shareholdings

As at 28 July 2010, the following significant shareholders of 3% or more of the ordinary share capital of the Company had been notified to the Company:

 

No. of Ordinary Shares

% of issued share capital

Octopus Investments Limited

2,277,240

7.40%

ISIS Equity Partners L.L.P.

1,822,000

5.92%

NVM Private Equity Limited

1,655,513

5.38%

Williams de Broë Limited

1,446,694

4.70%

MD Barnard & Co

1,245,413

4.05%

Artemis Investment Management Ltd

1,204,788

3.92%

Brewin Dolphin limited (Group)

991,676

3.22%

AXA (Institutional Group)

951,416

3.09%


As at 28 July 2010, 0.89% (held by Directors) of the issued share capital was not in public hands.

The authorised share capital of the Company is £42,000,000 divided into 420,000,000 ordinary shares of 10 pence each.

 

Admission Document

AIM Rule 26 Disclaimer

The attached Admission Document dated 5 April 2007 (the “Admission Document”) is being furnished for information purposes only in accordance with Rule 26 of the AIM Rules for Companies.

The Admission Document does not constitute an offer to sell or an invitation to purchase ordinary shares and/or other securities in IS Pharma PLC (the “Company”) in any jurisdiction and is not intended to form the basis of any investment decision or any other decision concerning the Company, its ordinary shares and/or other securities. The ordinary shares have not been nor will they be, registered under the US Securities Act of 1933, as amended, or under the securities laws of any state of the United States or under the applicable securities laws of Australia, the Republic of South Africa, New Zealand, Japan or Canada. Subject to certain exceptions, the ordinary shares may not directly or indirectly be offered or sold,  in the United States, Australia, the Republic of South Africa, New Zealand, Japan or Canada or for the benefit of any US person (as defined under Regulation S under the Securities Act).

The Admission Document may not be distributed or reproduced without the prior written consent of the Company.

While the information provided in the Admission Document was believed to be accurate as of 25 April 2007, the Company and its Directors do not make any representations or warranties, express or implied, nor do they accept any responsibility or liability, as to the accuracy or completeness of such information. Nothing contained within the Admission Document is or should be relied upon as a promise or representation as to the future performance or prospects of the Company. The information provided in the Admission Document only speaks as of 5 April 2007 and the Company and its Directors expressly disclaim any obligation to provide any updates to the information contained in the Admission Document.

Accept

Circulars

Notice of Annual General Meeting – 27 July 2010

Form of proxy – for AGM on 27 July 2010

Proposed Acquisition of Speciality European Pharma International AG

Accept

Result of Annual General Meeting held on 27 July 2010

Download the voting result PDF

Result of Annual General Meeting held on
28 July 2009

Download the voting result PDF

Result of General Meeting held on 21 April 2008

Download the voting result PDF